Company / EPS (Diluted)
SELLAS Life Sciences Group, Inc. EPS (Diluted) History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.50
FY2024
5-year range
-$10.92 / -$0.50
FY2020-FY2024
Trend
+76.5%
vs FY2023
Sector context
#71 of 204
Health Care
What the data says
At $-0.50, SELLAS Life Sciences Group, Inc.'s eps (diluted) ranks #71 of 204 in the Health Care sector. EPS (Diluted) has fluctuated over the past 7 years, ranging from $-10.92 in FY2020 to $-0.50 in FY2024.
Based on SEC 10-K filings.
-0.50 in FY2024.
Improved from $-1.34 to $-0.50 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#71 of 204 in Health CareTop 35% of 204This company -$0.50 Sector average -$0.89
▼
+43.6% above sector average
Key checks
Key Insights
- In FY2024, eps (diluted) increased 76.5% year-over-year.
- Ranks #71 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$0.50 | +76.5% |
| FY2023 | -$2.13 | -59.0% |
| FY2022 | -$1.34 | +36.5% |
| FY2021 | -$2.11 | +80.7% |
| FY2020 | -$10.92 | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | -$6.13 | -621.2% |
| FY2015 | -$0.85 | -51.8% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026